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ABSTRACT 
L-Amino acid deaminase from Proteus 
myxofaciens (PmaLAAD) is a membrane 
flavoenzyme which catalyzes the deamination of 
neutral and aromatic L-amino acids into -keto 
acids and ammonia. PmaLAAD does not use 
dioxygen to re-oxidize reduced FADH2 and thus 
does not produce hydrogen peroxide; instead, it 
uses cytochrome b-like protein as electron 
acceptor. Although the overall fold of this enzyme 
resembles that of known amine or amino acid 
oxidases, it shows specific structural features: an 
additional, novel + subdomain placed close to 
the putative transmembrane α-helix and to the 
active-site entrance, a FAD isoalloxazine ring 
exposed to solvent, and a large and accessible 
active site suitable to bind large hydrophobic 
substrates. In addition, PmaLAAD requires 
substrate-induced conformational changes of part 
of the active site, in particular Arg316 and 
Phe318, to achieve the correct geometry for 
catalysis. These studies are expected to pave the 
way for rationally improving the versatility of this 
flavoenzyme, which is critical for biocatalysis of 
enantiomerically pure amino acids. 
 
A variety of enzymes has been used to 
prepare chiral pharmaceutical and agricultural 
compounds containing enantiomeric amine or 
amino acid groups. Among these are 
aminotransferases (AT, EC 2.6.4.X), lipases (EC 
3.1.1.X), amine oxidases (EC 1.4.3.22), amino 
acid dehydrogenases (EC 1.4.1.X) and amino acid 
oxidases (EC 1.4.3.X) (1,2). 
The deracemization of a racemic amino acid 
to obtain the L-configuration was achieved by 
using a stereoselective D-amino acid oxidase 
(DAAO, EC 1.4.3.3) followed by chemical 
reduction. The second step iteratively converts the 
imino acid produced (from the D-amino acid) 
back into a D,L-mixture to obtain the full 
resolution of the racemic mixture into the L-
enantiomer (1). This approach requires stable 
recombinant DAAOs possessing wide substrate 
specificity as well as variants engineered to act on 
synthetic amino acids (3). 
Amino acid oxidases with reverse 
stereoselectivity are also well-known 
flavooxidases, mainly produced by snakes or by 
microorganisms. In particular, L-amino acid 
oxidases (LAAO, EC 1.4.3.2) catalyze the 
stereoselective oxidative deamination of L-amino 
acids into the corresponding -keto acids and 
ammonia: the re-oxidation of FADH2 by 
dioxygen then generates H2O2 (4). These 
flavoenzymes catalyze an irreversible reaction 
(differently from AT) and do not require a specific 
step of cofactor regeneration, as otherwise 
required by the NAD-dependent dehydrogenases. 
However, owing to the problems associated with 
overexpression of snake venom LAAOs in 
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recombinant hosts and the limited substrate 
acceptance of the microbial counterparts, no 
appropriate LAAOs for biocatalysis are available 
(4). 
L-amino acid deaminases (LAADs) 
represent a suitable alternative to LAAOs. LAAD 
(first identified in the genera Proteus, 
Providencia and Morganella) catalyzes the 
deamination of L-isomer of amino acids, yielding 
the corresponding -keto acids and ammonia 
without any evidence of H2O2 production. LAAD 
from Proteus myxofaciens (PmaLAAD), 
expressed in the E. coli K12 strain, shows a 
preference for L-amino acids containing aliphatic, 
aromatic and sulphur-containing side chains (5). 
Although the reaction catalyzed by LAAD is of 
both scientific and practical interest (5-7), no 
details about its structural-functional 
relationships and biological significance have 
been reported so far. 
In order to gain more insight into the 
properties of LAAD, we expressed the P. 
myxofaciens enzyme in E. coli and demonstrated 
that it is a membrane flavoenzyme employing a 
cytochrome b-like protein as electron acceptor. 
By using protein engineering studies we were able 
to produce a truncated, soluble form (PmaLAAD-
01N), which was crystallized. Its structural and 
biochemical characterization clearly shows that 
LAAD does not belong to the LAAO subfamily 
of flavo-oxidases, and is characterized by a large 
and open active site. These studies will provide 
the strong background needed to rationally alter 
the versatility of this flavoenzyme: engineered 
LAAD variants will represent the key to novel 
applications within the field of amino acids 
biocatalysis. 
 
 
EXPERIMENTAL PROCEDURES 
 
Cloning of PmaLAAD Wild-type and 
VariantsThe gene encoding for LAAD from 
Proteus myxofaciens (newly classified as 
Cosenzaea myxofaciens) (8) cloned into the NdeI 
and SalI restriction sites of the pET21a expression 
plasmid (Merck) was a generous gift from 
Wolfgang Kroutil (University of Graz, Austria). 
PmaLAAD-00N, -01N, -02N and -00C 
variants (Fig. 1) were produced by PCR. 
PmaLAAD wild-type gene was amplified using 
the upstream primers Var00-UP (5’-
TAGGCTAGCAACATTTCAAGGAGAAAGC
TAC-3’), Var01-UP (5’-
TAGGCTAGCATGGTTCGCCGTGATGGTAA
A-3’) or VAR02-UP (5’-
ATTGCTAGCGCCCTGCCATCAGAATCTGA
TG-3’) or VAR00C-UP (5’-
TAGCATATGAACATTTCAAGGAGAAAGC
TAC-3’); as downstream primer, the primer 
Var00-DN (5’-
GCACGGATCCTTATTACTTCTTAAAACGA
TCCAAACTAAACGG-3’) was used for the -
00N, -01N and -02N mutants and VAR00C-DN 
(5’-
CGCACCTCGAGCTTCTTAAAACGATCCAA
AC-3’) for the -00C mutant. The primers were 
designed to insert a NheI restriction site at the 5’-
end and a BamHI restriction site at the 3’-end of 
the amplification products for PmaLAAD-00N, -
01N and -02N, and a NdeI site at the 5’-end and a 
BamHI site at the 3’-end of the amplification 
product for PmaLAAD-00C. The amplification 
products (Pma-VAR00, -VAR01 and -VAR02 
genes) were subcloned into the NheI and BamHI 
restriction sites of the pET11a-His vector (a 
modified pET11a vector encoding a 6xHisTag 
sequence which is added at the N-terminus of the 
recombinant protein) (9), generating the pET11a-
His-PMA00, pET11a-His-PMA01 and pET11a-
His-PMA02 plasmids. Similarly, the pET24b 
plasmid was used to generate the pET24b-
PMA00C-His expression plasmid by using the 
NdeI and XhoI restriction sites. The expressed 
proteins possess a HisTag sequence (Fig. 1). The 
sequences of the cloned genes were confirmed by 
gene sequencing. 
 
Screening of Expression Conditions for 
PmaLAAD Wild-type and VariantsExpression 
conditions for PmaLAAD and its variants were 
screened by a simplified 96-well microplate 
factorial design approach (10). Four different E. 
coli strains (E. coli BL21(DE3), 
BL21(DE3)pLysS, Origami2(DE3) and 
Rosetta2(DE3)pLysS strains - Novagen) and two 
media (LB or modified TB, to which 10 g/L 
glycerol was added) were used. After overnight 
incubation at 28 °C, protein expression was 
induced by adding 0.005 or 0.1 mM final 
concentration of IPTG. Cells were collected after 
4 h (at 28 °C) or 20 h (at 15 °C). PmaLAAD 
expression was assessed by Western blot analysis 
using anti-HisTag antibodies (Santa Cruz 
Biotechnology, Santa Cruz, CA), as well as by 
activity assay on cell lysates by employing the 
spectrophometric assay (see below). 
 
Expression and Purification of PmaLAAD 
Wild-type and VariantsRecombinant wild-type 
and variants of PmaLAAD were expressed in E. 
coli BL21(DE3) strain under the following 


conditions: cells (from a single colony) were 
grown in modified TB medium containing 10 g/L 
glycerol, to which 100 g/mL ampicillin was 
added (or 30 g/mL kanamycin for PmaLAAD-
00C). Protein expression was induced by adding 
0.1 mM IPTG at an OD600nm = 0.5; after 4 hours 
of growth at 28 °C, cells were harvested by 
centrifugation. 
E. coli recombinant cells expressing 
PmaLAAD variants were disrupted by sonication 
in lysis buffer (50 mM potassium phosphate, pH 
7.0, 5 mM MgCl2). The cell lysate was separated 
from the cell debris by centrifugation at 38,500 g 
for 1 h yielding the insoluble fraction of the cell 
lysate and the crude extract containing the soluble 
proteins and membrane fragments. For wild-type 
PmaLAAD, ultracentrifugation of the latter 
fraction at 150,000 g for 2 h produced a 
membrane fraction (pellet) and a cytoplasmic 
fraction (supernatant). The membrane fraction 
was re-suspended in 2.5 mL of 50 mM potassium 
phosphate, pH 7.0, stored at -80 °C, then thawed 
and diluted 5-fold in 20 mM triethanolamine-HCl, 
pH 7.5: centrifugation at 16,000 g for 10 min 
yielded two phases at different density; see Fig. 2 
for details. 
Recombinant PmaLAAD-00N, -00C and -
01N variants from the soluble fraction of the 
lysates (crude extract) were purified by using 
metal-affinity chromatography on a HiTrap 
chelating column (5 mL, GE Healthcare, Little 
Chalfont, United Kingdom) using 50 mM 
potassium phosphate buffer, pH 7.5. In the case of 
PmaLAAD-01N, contaminant proteins bound to 
the column were eluted with two steps at 25 and 
80 mM imidazole, while the variant was eluted at 
200 mM imidazole. For crystallographic studies, 
the purity of PmaLAAD-01N was increased by 
loading the purified protein (13.7 mg/mL) onto a 
second HiTrap chelating column (1 mL): elution 
was performed using increasing concentrations of 
imidazole (25, 50, 125 and 500 mM). 
PmaLAAD-00N and -01N were analysed by 
size-exclusion chromatography using a Superdex 
200 Increase 10/300 column (GE Healthcare). 
 
Activity AssayThe activity on L-Phe was 
assayed spectrophotometrically by following the 
formation of the product phenylpyruvate at 321 
nm, a wavelength at which the extinction 
coefficient of the substrate is negligible (5). The 
protein sample was added to 2 mL (final volume) 
of 25 mM L-Phe in 50 mM potassium phosphate 
buffer, pH 7.5, and incubated for 2 min at 25 °C. 
Every 30 s an aliquot of 400 L was transferred 
into a plastic cuvette containing 400 L of 3 N 
NaOH to stop the reaction and allow colour to 
develop. One enzymatic unit corresponds to the 
amount of enzyme that converts 1 mol of L-Phe 
per minute. 
Apparent Km, kcat and Vmax values for L-Phe 
were determined by the phenylpyruvate 
production assay using increasing substrate 
concentrations, at 25 °C and oxygen air saturation 
(0.253 mM). 
The same assay was used to investigate the 
ability of commercial quinones (anthraquinone-
2,6-disulphonate, anthraquinone-1,5-
disulphonate, 2-hydroxy-1,4-naphtoquinone, 
menadione, duroquinone and juglone), using 
phenazine methosulphate as mediator, or artificial 
electron acceptors (indigotetrasulphonate, 
gallocyanine, 2,6-dichlorophenolindophenol / 
phenazine methosulphate, cytochrome c and 
nitroblue tetrazolium) to stimulate the activity of 
PmaLAAD-00N in the absence of membranes. 
All compounds were used at 50 M final 
concentration, the only exception being phenazine 
methosulphate which was used at 800 M final 
concentration. 
The activity of PmaLAAD on L-Phe in the 
presence of exogenous membranes prepared from 
E. coli, Streptomyces venezuelae and human 
glioblastoma T98G cells was investigated using 
the spectrophotometric assay. 
The deamination reaction of PmaLAAD on 
L-amino acids in the presence of commercially 
available E. coli lipid extracts (Avanti Polar 
Lipids, Alabaster, AL) was investigated by means 
of a polarographic method based on an oxygen 
electrode (O2-consumption) assay (11). This 
assay couples the re-oxidation of the reduced 
flavin in PmaLAAD with an electron acceptor 
system that, in turn, consumes dioxygen (see 
Results section for details). This assay was also 
employed to investigate the substrate specificity 
of PmaLAAD on a number of L-amino acids. 
 
Determining optimal pH and Temperature 
To investigate the pH dependence of the initial 
rate of phenylpyruvate production, wild-type 
PmaLAAD enzymatic activity was assayed at 
different pH values on 25 mM L-Phe in a 
multicomponent buffer (160 mM Tris–HCl, 160 
mM Na2CO3, 160 mM H3PO4, 650 mM KCl and 
1% glycerol) (12). Data points were fitted based 
on the equation for two dissociations: Y = a + 
b(10pH-pKa1) / (1 + 10pH-pKa1) + [b - c(10pH-pKa2) / (1 
+ 10pH-pKa2)] (12). 
Temperature dependence of PmaLAAD 
activity was assayed by measuring the production 
of phenylpyruvate as described above at different 
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temperatures, in 50 mM potassium phosphate, pH 
7.5, using 25 mM L-Phe as substrate. 
 
Spectral MeasurementsAbsorbance spectra 
in the UV–visible region of PmaLAAD variants, 
as well as ligand-binding experiments, were 
recorded using a Jasco V-560 spectrophotometer 
(Jasco Europe, Cremello, Italy) as previously 
reported (13). 
Anaerobic samples were prepared in 
anaerobic cuvettes by applying ten cycles of 
evacuation and then flushing with oxygen-free 
argon. Flavin reduction was carried out by adding 
25 mM (final concentrations) of the substrate L-
Phe to samples containing  15 M enzyme; 
reduction of the cofactor for PmaLAAD-00N 
variant was performed both in the absence and in 
the presence of E. coli membranes. 
Photoreduction experiments were carried out 
at 4 °C using an anaerobic cuvette containing 18.5 
M PmaLAAD-00N or 13.1 M PmaLAAD-
01N, 5 mM EDTA and 0.5 M 5-deaza FAD. The 
solution was photoreduced using a 250-W lamp 
and the progress of the reaction was monitored 
spectrophotometrically (13,14). At the end of the 
reaction, FAD cofactor was re-oxidized 
anaerobically by adding 5.5 M (final 
concentration) benzyl viologen or by flushing O2. 
Photoreduction experiments for PmaLAAD-00N 
were also performed in the presence of E. coli 
membranes. 
Binding experiments of carboxylic acids and 
sulphite to PmaLAAD-00N and -01N variants 
were performed by adding small volumes (5 – 50 
L) of concentrated stock solutions (0.1 mM – 1 
M) to samples containing 0.8 mL of  15 M 
enzyme and following the changes in the visible 
absorbance spectrum of the flavin cofactor 
(13,14).  
Far-UV CD spectra of PmaLAAD-00N and -
01N variants were recorded using a Jasco J-815 
spectropolarimeter equipped with a software-
driven Peltier-based temperature controller: the 
cell path was 0.1 cm (15). 
All spectral measurements were recorded at 
15 °C in 50 mM potassium phosphate buffer, pH 
7.5, except where stated otherwise. 
 
Crystallization, Structure Determination and 
RefinementCrystallization trials of PmaLAAD-
01N (≈ 10 mg/mL) were performed using the 
sitting-drop vapour diffusion method with an 
Oryx-8 crystallization robot (Douglas Instr., East 
Garston, UK). After a week at 4 °C, crystals were 
observed under the following growth conditions: 
15% PEG 6K, 0.1 M MES (pH 6.5), 10% MPD. 
They were cryoprotected in a stabilizing solution 
(20% PEG 6K, 0.1 M MES, pH 6.5, 10% MPD) 
supplemented with 15% glycerol, and flash-
cooled in liquid nitrogen. A single crystal, 
belonging to the monoclinic space group P21, 
diffracted up to 2.0 Å resolution. Diffraction data 
were collected at the ESRF beamline ID23-2 
(Grenoble, France) and processed with XDS (16) 
and SCALA (17).  
The PmaLAAD-01N structure was solved by 
molecular replacement using the program Phaser 
(18), with the β-subunit of sarcosine oxidase from 
Pseudomonas maltophilia (PDB code 2GAG) 
(19) as a search model. Two protein molecules (A 
and B chains) were located in the crystal 
asymmetric unit and were subjected to rigid-body 
and restrained refinement using Phenix (20). The 
amino acid sequence of the model was modified 
to match the correct sequence and manually fitted 
to the electron density using the program Coot 
(21). A set of restrained refinement cycles were 
performed using the programs Phenix (20) and 
Refmac (22). The final refined PmaLAAD-01N 
structure (Rfactor = 17.7%, Rfree = 20.9%) contains 
2x447 protein residues (28-474), 2 FAD co-
factors, and 518 water molecules, with good 
stereochemical parameters. Poor electron density 
is only present at the N- and C-terminus (residues 
28 and 474 of both A and B chains). 
For soaking experiments and data collection, 
native PmaLAAD-01N crystals were removed 
from the crystallization drop with a nylon loop 
and soaked overnight in a mixture of their 
stabilizing solution (see above) supplemented 
with 20 mM anthranilate. The soaked crystals 
were quickly pulled through a drop of 
cryoprotectant before being flash-cooled in liquid 
nitrogen. A single crystal, belonging to 
monoclinic space group P21, diffracted up to 1.75 
Å resolution (data collection and processing as 
above).  
The structure of the PmaLAAD-
01N/anthranilate complex was determined by 
molecular replacement using the program Phaser 
(18), with the structure of PmaLAAD-01N as a 
search model. Two protein molecules were 
located in the crystal asymmetric unit (A and B 
chains). The structure was then remodelled with 
Coot (21) and subjected to restrained refinement, 
with anisotropic B-factors, using the program 
Refmac (22). After a few cycles of refinement, the 
2Fo-Fc electron density map showed structural 
details that allowed unambiguous modelling of 
the bound substrate analogue. The final model 
(Rfactor = 15.6%, Rfree = 19.7%) contains 2x447 
protein residues (28-474), 2 FAD cofactors, 2 
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anthranilate molecules, and 546 water molecules, 
with good stereochemical parameters. Poor 
electron density is present at the 28-31 and 337-
342 regions and at the C-terminus (residue 474) 
of both A and B chains. 
All data reduction and refinement statistics 
for both protein models (PmaLAAD-01N and 
PmaLAAD-01N/anthranilate complex) are 
reported in detail in Table 1. The stereochemical 
quality of the models was assessed with 
MolProbity (23).  
The atomic co-ordinates and structure factors 
for PmaLAAD-01N and PmaLAAD-
01N/anthranilate complex (codes 5FJM, 5FJN 
respectively) have been deposited in the Protein 
Data Bank (http://www.wwpdb.org/). 
 
Phylogenetic AnalysesProteins 
homologous to PmaLAAD were identified with 
HMMER web server (24) using the 
“Representative Proteomes” database (25). 
Sequences sharing an identity > 90% with 
PmaLAAD were filtered using CD-HIT Suite 
(26). In addition, amino acid sequences 
possessing an identity with PmaLAAD < 28% 
were discarded. Alignment was performed using 
the MUSCLE algorithm in SeaView software 
(27). Maximum-likelihood phylogenetic (ML) 
tree of LAAD sequences was built using PhyML 
3.0 server (28). Confidence of branching patterns 
was assessed by bootstrapping (100 boostrap 
samples were used) (29). The resulting ML tree 
was visualized in FigTree v1.4.2 
(http://tree.bio.ed.ac.uk/software/figtree/). 
 
 
RESULTS 
 
Purification of Recombinant Wild-type 
PmaLAADRecombinant PmaLAAD (the 
sequence of which is reported in Fig. 1B) was 
expressed in E. coli BL21(DE3) cells. After cell 
lysis by sonication and centrifugation, the 
PmaLAAD activity was fully recovered in the 
crude extract, as assayed by following the 
absorbance change at 321 nm due to the 
conversion of L-Phe into phenylpyruvic acid. 
After ultracentrifugation of the crude extract, the 
recombinant enzyme was mainly associated to the 
membrane fraction (i.e. in the pellet fraction) 
which was re-suspended in 50 mM potassium 
phosphate buffer, pH 7.5, obtaining a ≈ 2-fold 
increase in specific activity (Fig. 2). 
Interestingly, thawing, diluting (5-fold) in 20 
mM triethanolamine-HCl, pH 7.5, and 
centrifuging the membrane fraction stored at -80 
°C resulted in a phase separation: the lower, 
denser phase contained about half of the 
PmaLAAD of the sample (based on the enzymatic 
activity and SDS-PAGE analysis) and showed a 
further ≈ 2.5-fold increase in specific activity, 
reaching 2.9 U/mg of protein, with an overall 
yield of 33% (Fig. 2). Based on the purity degree 
(29%, see lane 7 in Fig. 2B, left panel), a kcat = 8.5 
s-1 was estimated. Owing to the failure to produce 
a soluble, membrane-free preparation of wild-
type PmaLAAD, chromatographic steps were not 
effective in purifying enzyme. 
In addition,  N- and C-terminal His-tagged 
full-length proteins were produced (PmaLAAD-
00N and -00C, respectively, Fig. 1) and expressed 
at a level similar to that of wild-type PmaLAAD 
by using BL21(DE3) or Origami E. coli strains. 
When the crude extract containing PmaLAAD-
00N (specific activity on L-Phe of 0.8 U/mg 
protein) was loaded on a HiTrap chelating column 
it separated into two fractions: the flow-through 
containing the active enzyme ( 500 U/L 
fermentation broth, 90% of purification yield) 
associated to membrane fragments, and the 
fraction eluted at 0.2 M imidazole which 
contained a significant part of PmaLAAD-00N 
(devoid of membranes). Following dialysis to 
eliminate imidazole, the latter fraction showed a 
purity degree  90% (as estimated by SDS-PAGE 
analysis, lane 5 in Fig. 2B, central panel) and was 
fully stable (see spectral properties, below). 
However, the measured LAAD activity was only 
marginal (5 U/L fermentation broth); therefore, 
this fraction was named “quasi-inactive” 
PmaLAAD-00N. Similar results were obtained 
for the PmaLAAD-00C variant: again, after 
loading on the HiTrap chelating column, 
enzymatic activity was detected mainly in the 
flow-through fraction ( 250 U/L fermentation 
broth), while the fraction eluted at 0.5 M 
imidazole contained a significant part of 
PmaLAAD-00C protein but showed only 
marginal LAAD activity (< 2%), and a purity of  
70% (as estimated by SDS-PAGE analysis), not 
shown. 
 
Biochemical Properties of Partially Purified, 
Membrane-bound PmaLAADThe specific 
activity of PmaLAAD in the crude extract, which 
contains membranes, on 25 mM L-Phe as 
substrate was  0.6 U/mg protein (assayed as 
production of phenylpyruvic acid). The 
dependence of the initial rate on L-Phe 
concentration is shown in Fig. 3A: the Km,app = 
3.27 ± 0.96 mM and Vmax,app = 1.35 ± 0.08 U/mg 
protein values are in good agreement with those 
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reported in the literature (Km,app = 2.3 mM, Vmax,app 
= 2 U/mg) (5). As a result of the 12% purity 
degree of PmaLAAD in the crude extract, a kcat = 
8.3 s-1 was estimated. No substrate inhibition was 
evident up to 100 mM L-Phe. On the same 
enzyme preparation, the activity on L-Phe was 
also assayed as O2 consumption (i.e. by 
polarographic assay) (11), yielding an identical 
specific activity.  
From this evidence we conclude that the 
membrane-containing PmaLAAD preparation 
catalyzes the O2-dependent oxidative deamination 
of L-Phe. 
By employing the O2-consumption assay we 
investigated the relative substrate specificity of 
PmaLAAD toward natural and synthetic amino 
acids: the polarographic assay was carried out 
using a fixed volume of membrane-associated 
PmaLAAD (corresponding to  0.5 mg of total 
membrane proteins) and 25 mM substrate 
concentration. As shown in Table 2, PmaLAAD 
is specific for aromatic, neutral L-amino acids; a 
low activity was assayed towards small, charged 
or polar L-amino acids. Notably, a significant 
activity was also measured on the synthetic amino 
acid L-phenylalanine ethylester (whose -
carboxylic group is esterified) and on L-DOPA 
(33% and 56.7% in comparison to L-Phe, 
respectively). No significant activity was assayed 
with D-amino acids (Table 2). 
The pH dependence of PmaLAAD activity 
was evaluated on the sample from the membrane 
fraction by using the spectrophotometric assay in 
the 3 to 10 pH range (12). The highest activity is 
apparent at neutral pH (between 7 and 7.5) and is 
negligible below pH 5 and above pH 9 (Fig. 3B). 
Concerning the temperature dependence, the 
activity of PmaLAAD linearly increased up to 50 
°C and then rapidly decreased, becoming 
negligible at 70 °C (Fig. 3C). This behaviour 
resembles that reported for LAAD from P. 
mirabilis (optimal temperature of 45 °C) (30). 
Notably, PmaLAAD in the crude extract 
showed a fairly good stability since it showed a 
50% residual activity after 24 hours of incubation 
at 25 °C. The enzyme retained ≈ 50% and ≈ 75% 
of the original activity when stored for 1 month in 
the presence of 10% glycerol at -20 °C and at -80 
°C (even without glycerol), respectively. 
Overall, the properties of this PmaLAAD 
preparation seem to satisfy the requirements for 
application in biocatalysis of natural and 
unnatural amino acids (2). 
 
Biological Activity of PmaLAAD: Effect of 
MembranesThe enzymatic activity (assayed as 
production of phenylpyruvic acid) of purified, 
membrane-free, quasi-inactive PmaLAAD-00N 
is very low (see above): notably, it was 
significantly enhanced by adding E. coli 
membranes and sonication. Actually, the addition 
of an amount of membranes from E. coli cells (not 
expressing PmaLAAD) corresponding to ≈ 0.30 
mg of cells for each g of enzyme increased the 
PmaLAAD-00N activity by ≈ 50-fold. No further 
increase in enzymatic activity was obtained using 
larger amounts of membranes. As a control, 
sonication of PmaLAAD-00N in the absence of 
exogenous membranes resulted in a 6-fold 
decrease in the original, low enzymatic activity. 
Notably, recovery of PmaLAAD activity 
depended on the membrane’s source: no recovery 
of the enzymatic activity was observed using 
membranes from the micro-organism 
Streptomyces venezuelae while a low, partial 
recovery was apparent (2.7-fold) using 
membranes from human glioblastoma T98G cells. 
Similarly to PmaLAAD-00N, a  32-fold increase 
in enzymatic activity was apparent by adding E. 
coli membranes prepared from 2.25 mg cells, to 
75 g of purified PmaLAAD-00C. 
The dependence of PmaLAAD-00N activity 
on a putative molecular partner associated to the 
bacterial membrane was investigated by mixing 
the purified enzyme variant with two 
commercially available E. coli lipid extracts 
(Avanti Polar Lipids). Mixing 150 g of 
PmaLAAD-00N with 4.5 mg of Total Lipid 
extract (containing 17.6% unknown components, 
mainly lipoproteins) resulted in a slight (4-fold) 
increase in activity, which is significantly lower 
than the activity recovery observed using the 
same amount of E. coli membranes (= 32-fold). 
Employing the Polar Lipid extract (with a higher 
degree of purity) an even lower increase in 
enzymatic activity was apparent (1.6-fold, Table 
3). To exclude any inhibitory effect of a 
component of the lipid extracts, 150 g of 
PmaLAAD-00N were mixed with 2.25 mg of 
lipid extract and a corresponding amount of E. 
coli membranes (22.5 mg): the recovery of the 
enzymatic activity resembled the value observed 
for E. coli membranes only. 
Altogether, these results suggest that a 
specific membrane partner(s) -- which is(are) 
available in E. coli membrane preparations -- is 
required for the purified, quasi-inactive 
PmaLAAD-00N to recover the enzymatic 
activity. Membranes from an unrelated source or 
a hydrophobic environment, such as the one 
provided by purified lipid extracts, are not 
suitable for recovering PmaLAAD activity. 

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Spectral Characterization of Purified 
PmaLAAD-00NThe spectral properties were 
assessed using the membrane-devoid PmaLAAD-
00N variant because of its higher purity compared 
to the form lacking the HisTag and the absence of 
membranes affecting the measurements. 
PmaLAAD-00N shows the canonical absorbance 
spectrum of FAD-containing flavoproteins with 
three main peaks at 277, 380 and 456 nm (Fig. 
4A). The ratio between the absorbance at 277 nm 
and at 456 nm is  8.9, and the estimated molar 
extinction coefficient is 14168 M-1cm-1 at 456 nm. 
The absorbance spectrum of PmaLAAD-00C 
resembled that of PmaLAAD-00N (data not 
shown): this indicates that the location of the 
HisTag does not affect the flavin environment of 
PmaLAAD. The far-UV circular dichroism 
spectrum shows that PmaLAAD-00N is folded 
and contains secondary structure elements (not 
shown). 
Amino acid oxidases are known to interact 
with a number of carboxylic acids, yielding 
specific spectral modifications and thus 
representing useful active-site probes (4,31,32). 
The binding to PmaLAAD-00N of various 
compounds known as DAAO and/or LAAO 
active-site ligands (14,33,34) was investigated in 
the absence and in the presence of E. coli 
membranes (corresponding to  0.30 mg of cells 
for each g of PmaLAAD-00N). No spectral 
perturbations were evident up to  0.4 M sodium 
benzoate, suggesting that PmaLAAD-00N cannot 
bind this well-known DAAO ligand (31,35). 
However, when the same experiment was 
performed using anthranilate (2-aminobenzoate), 
specific spectral perturbations were observed in 
the 400- to 500-nm and in the 520- to 600-nm 
range (Fig. 4C); the latter spectral changes are due 
to the formation of a charge-transfer complex 
between the ligand and the FAD cofactor, as 
observed for other amino acid oxidases (31,35). 
These absorbance changes were more evident in 
the absence of membranes: from the absorbance 
changes at 533 nm as a function of anthranilate 
concentration, a Kd of 18.4 ± 4.4 mM was 
calculated (n=3, Fig. 4C, inset). The same 
experiment was performed using kojic acid as 
ligand (Fig. 4E), yielding a general increase in 
absorbance in the visible region of the spectrum 
with a saturation behaviour (Kd = 3.0 ± 0.3 mM) 
(n=3, Fig. 4E, inset). Overall, PmaLAAD-00N 
binds selected carboxylic acids, resulting in 
specific alterations of the visible spectrum of the 
flavin cofactor. 
We then demonstrated that the flavin 
cofactor bound to PmaLAAD is catalytically 
competent. Actually, when the PmaLAAD-00N 
variant was mixed under anaerobic conditions 
with an excess of substrate (25 mM L-Phe), the 
flavin cofactor rapidly reacted with the substrate, 
yielding the typical absorbance spectrum of the 
reduced FAD (i.e. bleaching of the 450-nm peak 
in the dead time of mixing for the membrane-free 
preparation) (Fig. 4A). Notably, the time course of 
flavin reduction was identical under aerobic 
conditions. We could then establish the reductive 
half-reaction catalyzed by PmaLAAD: 
FAD + L-Phe  ∆ FADH2 + phenylpyruvic acid 
(eq. 1) 
No spectral perturbations resembling flavin 
reduction were observed by adding sulphite to 
PmaLAAD-00N instead (up to  0.45 M Na2SO3), 
this suggesting divergences in FAD reactivity 
between PmaLAAD and the enzymes belonging 
to the oxidase class of flavoproteins (33). 
Anaerobic photoreduction of PmaLAAD-
00N in the presence of 5 mM EDTA and 0.5 M 
5-deaza-FAD generated the reduced FAD 
cofactor form after 5 min of exposure to intense 
light radiation (Fig. 4G). A large amount of the 
anionic semiquinone flavin form was evident, as 
made apparent by the large increase in a peak at  
380 nm, an effect due to intense light irradiation. 
A full re-oxidation of membrane-free, fully 
photoreduced PmaLAAD-00N requiring minutes 
to completion was observed both by admitting O2 
(see below) than by adding benzyl viologen (Fig. 
4G). 
 
Formation of the Reduced Form of a 
Cytochrome b-like Protein During PmaLAAD-
00N Reaction in MembranesThe time course of 
FAD reduction of PmaLAAD-00N in the 
presence of membranes by an excess of L-Phe 
under anaerobic conditions was clearly biphasic: 
a large, rapid decrease at 450 nm was followed by 
a slower and smaller further decrease (taking  15 
min to completion, Fig. 4B). Interestingly, three 
narrow absorbance peaks are evident following 
full FAD reduction: one major peak at 429 nm and 
two minor peaks at 532 nm and 560 nm (Fig. 4B). 
These peaks correspond to the ones typically 
associated with the reduced form of cytochrome b 
(36), a small membrane protein usually associated 
with redox enzymes (37). For details concerning 
cytochromes in Proteous species see (38,39). 
Notably, when the same reaction was performed 
under aerobic conditions, the spectrum of the 
reduced cytochrome was observed only when the 
L-Phe concentration exceeded the concentration 
of dissolved O2 (i.e. at > 0.3 mM L-Phe). These 
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data demonstrate that in the presence of 
membranes, L-Phe deamination by PmaLAAD is 
coupled to reduction of a cytochrome b-like 
protein. 
In the presence of membranes, 1:1 (v/v) ratio 
corresponding to 30 mg of cells for each g of 
enzyme, the rate of flavin photoreduction of 
PmaLAAD-00N was increased (3.5 min to reach 
complete reduction, Fig. 4H) as compared to the 
same experiment in the absence of membranes. 
Notably, the isosbestic point at 410 nm observed 
in the photoreduction experiment in the absence 
of membranes was not conserved due to the 
formation of a Soret band of cytochrome b at 429 
nm. In the presence of membranes, too, a large 
amount of the anionic semiquinone flavin form 
was evident, as made apparent by the large 
increase in a peak at  380 nm due to intense light 
irradiation. 
 
O2-ReactivityThe L-Phe deamination 
activity of PmaLAAD in the presence of 
membranes is coupled to O2 consumption (see 
above). Dioxygen is absolutely required to 
produce phenylpyruvic acid from L-Phe under 
these experimental conditions: the rate constant 
for ketoacid production under anaerobic 
conditions is  3% of the value assessed at air 
saturation. Indeed, the reaction rate did not 
depend on O2 concentration since a similar 
apparent activity was determined at  10% O2-
saturation. 
Known LAAO and DAAO flavoenzymes 
employ O2 to re-oxidize the reduced FADH2 
cofactor yielding H2O2. Notably, when using 
wild-type PmaLAAD in the crude extract, which 
is associated to membranes, no halving of oxygen 
consumption was observed by adding a large 
excess of catalase, which converts H2O2 into H2O 
and ½ O2, to the reaction mixture of the 
polarographic assay, this demonstrating that no 
H2O2 was produced during the enzymatic 
reaction. Lack of H2O2 production was also 
confirmed by the classic o-dianisidine/peroxidase 
spectrophotometric, coupled assay used for 
flavoprotein oxidases (11). Similarly, no 
superoxide was produced by the PmaLAAD 
reaction since the O2 consumption was not 
modified by adding up to 24 U of superoxide 
dismutase.  
Opening the cuvette containing fully 
photoreduced membrane-devoid PmaLAAD-00N 
to air, conversion into the fully re-oxidized flavin 
spectrum required  20 min, showing a very 
limited dioxygen reactivity of reduced 
PmaLAAD-00N (kreox ≤ 0.08 s-1). Mixing the 
photoreduced membrane-devoid PmaLAAD-00N 
with buffer solutions equilibrated at increasing O2 
concentrations in the stopped-flow device (5-50% 
oxygen saturation, final concentration) did not 
yield the re-oxidized form of the flavin cofactor 
(33) during the measurement ( 2 min), as 
otherwise normally observed for flavo-oxidases. 
Altogether, these results demonstrate that the 
flavin molecule bound to PmaLAAD is quickly 
reduced by the substrate but it is not efficiently re-
oxidized by O2 since the rate constant is not 
sufficient for the observed turnover (0.08 vs.  8 
s-1, respectively). The O2 consumption observed 
in the presence of membranes is clearly not due to 
a direct, O2-induced re-oxidation of the flavin 
cofactor bound to the enzyme. We suggest that in 
membranes the reduced flavin form of PmaLAAD 
is re-oxidized by two oxidized cytochrome b-like 
proteins: 
E-FADH2 + 2cytox  ∆ E-FADox + 2cytred   (eq. 2) 
that then transfer the electrons through the 
respiratory chain to dioxygen yielding H2O. 
Actually, using 250 M antimycin A, an inhibitor 
of the respiratory chain, the O2-consumption of L-
Phe oxidation by PmaLAAD in resuspended 
membranes is drastically decreased ( 60%). 
The activity of purified, membrane-devoid 
PmaLAAD-00N was also detected using artificial 
electron acceptors, such as indigotetrasulphonate, 
gallocyanine, 2,6-dichlorophenolindophenol, 
cytochrome c and nitroblue tetrazolium. The 
highest activity was apparent with 2,6-
dichlorophenolindophenol /phenazine 
methosulphate (Em = 217 mV at pH 7.5): specific 
activity was 8-fold higher than the value 
determined with oxygen only. In contrast, a more 
modest increase in activity (3 to 4-fold) was 
observed when quinones, such as anthraquinone-
2,6-disulphonate, anthraquinone-1,5-
disulphonate, 2-hydroxy-1,4-naphtoquinone, 
menadione, duroquinone and juglone, were used 
as electron acceptors. Furthermore, adding 
duroquinone or juglone (50 M) to the 
PmaLAAD membrane-containing fraction or to 
purified PmaLAAD added of Polar Lipid extract 
(as in Table 3) resulted in a moderate,  2–fold 
increase in activity. 
 
Production and Properties of the Soluble 
PmaLAAD-01N VariantIn order to design a 
PmaLAAD variant not able to associate to 
membranes and thus suitable for crystallographic 
studies, the amino acid sequence of the wild-type 
protein was analysed using the TMPred server 
(40). A putative transmembrane -helix (residues 
8 to 27) was predicted in the N-terminal region 
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(Fig. 1A). Based on this prediction, two deletion 
variants were designed starting from Met28 
(PmaLAAD-01N) and Ala50 (PmaLAAD-02N), 
respectively. Both variants were produced with an 
additional HisTag sequence at the N-terminus to 
facilitate their purification (Fig. 1A,B). The 
PmaLAAD-02N variant was not characterized 
because of its low stability. 
The PmaLAAD-01N variant, lacking the 
putative transmembrane α-helix, was expressed 
by following the same protocol used for 
PmaLAAD and PmaLAAD-00N and was purified 
from the crude extract by HiTrap chelating 
affinity chromatography. PmaLAAD-01N is 
almost completely soluble:  25 mg of pure 
PmaLAAD-01N were purified from 1 L of culture 
with a > 90% purity (Fig. 2B, lane 5 in right 
panel). The enzymatic activity of the pure 
PmaLAAD-01N preparation was below detection 
even when exogenous E. coli membranes were 
added to the assay mixture. 
PmaLAAD-01N shows an absorbance 
spectrum very similar to that of PmaLAAD-00N, 
with an estimated molar extinction coefficient at 
458 nm of 12193 M-1cm-1 (Fig. 4A). In contrast, 
the far-UV circular dichroism spectrum of 
PmaLAAD-01N differs from the one recorded for 
the PmaLAAD-00N counterpart, showing, as 
expected, a decrease in -helix content (not 
shown). 
When analysed by size-exclusion 
chromatography, purified PmaLAAD-01N eluted 
in a single peak, corresponding to a molecular 
mass of 44.6±0.5 kDa (n = 3) kDa (slightly lower 
than the expected value of 49.9 kDa), thus 
indicating that it is monomeric in solution in the 
1-5 mg/mL protein concentration range. A similar 
result was obtained for the soluble fraction of full-
length PmaLAAD-00N ( 47 kDa). 
Similar to PmaLAAD-00N, PmaLAAD-01N 
did not bind benzoate and did not react with 
sulphite but did interact with anthranilate, 
yielding a spectral perturbation which resembles 
a charge-transfer complex (Kd = 36.7 ± 5.6 mM, 
Fig. 4D). PmaLAAD-01N was also titrated with 
2-aminobenzaldehyde: binding of this compound 
resulted in a large spectral change in the 500- to 
580-nm range (Kd of 0.31 ± 0.05 mM n=3, Fig. 
4F). 
When purified PmaLAAD-01N was mixed 
under anaerobic conditions with an excess of 
substrate (25 mM L-Phe), the FAD cofactor 
rapidly converted into the reduced form, thus 
demonstrating that it is catalytically competent. 
Notably, the time course of flavin reduction and 
the absorbance spectrum of the reduced enzyme 
form were identical under both aerobic and 
anaerobic conditions, pointing to a limited O2-
reactivity of the deleted PmaLAAD variant, too. 
Photoreduction of the FAD cofactor in 
PmaLAAD-01N was fully accomplished after  
10 min of illumination (with a large amount of 
anionic semiquinone formation) and the 
photoreduced enzyme was reverted to the 
oxidized form by mixing with benzyl viologen. 
Altogether, the spectral, binding and 
oligomerization properties of the deletion variant 
PmaLAAD-01N resemble those of the full-length 
enzyme. The main difference is its inability to 
associate with membranes, which prevents 
efficient L-Phe oxidation. 
 
Overall Structure of PmaLAAD-01NThe 
PmaLAAD-01N was solved at 2.0 Å resolution 
and refined to final R-factor and R-free of 17.7% 
and 20.9%, respectively. Data collection and 
refinement statistics are reported in Table 1. 
PmaLAAD-01N consists of two domains: a FAD-
binding domain (Fbd: residues 40-100, 203-276, 
413-474) similar to the glutathione reductase 2 
family (41) and a substrate-binding domain (Sbd: 
residues 28-39, 101-202, 277-412) (Fig. 5A). 
The Fbd is made up of a six-stranded β-sheet 
with β10-β3-β2-β14-β24-β23 topology flanked 
by a helix bundle formed by A1-A3-A6-A14 on 
one side and by a three-stranded β-sheet β11-β12-
β13 and helix A7 on the other side. The C-
terminal A15 and A16 helices (310) run 
orthogonally to strand β23 (Figs. 5B,C). The 
helices A1 and A14 of the helix bundle pack 
against the central six-stranded β-sheet with their 
N-termini directed toward the FAD molecule. 
Helix A3 forms an outer layer of the fold, running 
orthogonally behind the A1, A6 and A14 helices. 
On the same side, the 310 helix A2 flanks the 
pyrophosphate group of FAD. On the other side, 
the N-terminus of helix A7 is directed toward the 
FAD molecule. 
The Sbd consists of a mixed, eight-stranded 
β-sheet with β7-β8-β6-β16-β17-β18-β15-β22 
topology and is flanked by helices A4, A5, A12 
and the 310 helix A13. The long β15 and β22 
strands connect the Sbd and the Fbd, forming a 
four-stranded mixed β-sheet with β19 and β20. 
Another connection between the two domains is 
provided by strands β4 and β9 that form with 
strand β5 a small, anti-parallel, three-stranded β-
sheet (Fig. 5B). 
The Sbd is characterized by the presence of a 
long region of 67 amino acids nestled between 
strand β19 and helix A12: this subdomain shows 
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an +β structure whose arrangement is 
unprecedented, as suggested by a DALI search 
(42). The  region consists of four helices: A8, 
A9, A10 and A11; the β-region includes strand 
β20, which forms a parallel two-stranded β-sheet 
with β19 from the core of the Sbd, and an anti-
parallel two-stranded β-sheet built up by strand β1 
and β21. In particular, strand β1 belongs to the N-
terminal region of PmaLAAD-01N (residues 28-
39), which crosses the subdomain on the protein 
surface before inserting in the Fbd (Fig. 5A,B). 
Regarding the quaternary assembly, the two 
PmaLAAD-01N molecules in the crystal 
asymmetric unit face each other in the Sbd regions 
corresponding to the end of A3 and the following 
loop, to A4-β7-A5, to A6 and to β16-β17. The 
facing residues (25 in each monomer) make six 
salt bridges and two H-bonds (distances 3-3.5 Å). 
According to the program PISA (43), these 
interactions make the complex stable, but the 
overall buried surface area is modest, ≈ 700 Å2 for 
each monomer corresponding to ≈ 4% of the total 
accessible surface area. Thus, in agreement with 
size-exclusion chromatography experiments, the 
PmaLAAD-01N does not show any quaternary 
architecture and can be considered monomeric. 
 
Structural RelativesA DALI analysis (42) 
indicates that the PmaLAAD-01N tertiary 
structure resembles that of a series of FAD-
binding oxidoreductases, such as the β subunit of 
L-proline dehydrogenase from Pyrococcus 
horikoshii (PDB code 1Y56; DALI Z-score of 
42.3, residue identity of 23%) (44), glycine 
oxidase from Bacillus subtilis (PDB code 1C0I; 
DALI Z-score of 41.2, residue identity of 21%) 
(45), and the heterotetrameric sarcosine oxidase 
from Corynebacterium sp. U-96. (PDB code 
3ADA; DALI Z-score of 40.9, residue identity of 
23%) (46) and from Stenotrophomonas 
maltophilia (PDB code 2GAG; DALI Z-score of 
40.2, residue identity of 23%) (19) (Table 4). 
The structural relationship among all these 
proteins extends to an excellent conservation of 
tertiary structure, with a r.m.s. deviation ranging 
from 2.0 to 2.2 Å. The structural homology is 
particularly marked for the isolated Fbd, with a 
r.m.s. deviation in the 1.2- to 1.3-Å range, while 
for the isolated Sbd it ranges from 1.9 to 2.2 Å 
(Table 4). Although the general correspondence 
of secondary structure elements is maintained in 
both domains (Fig. 5C), the orientation of the Sbd 
is slightly different if the Fdb is used for the 
structural superimposition (Fig. 6A). Most 
importantly, the additional α+β subdomain 
present in PmaLAAD-01N (Fig. 5C) is absent as 
such in the other related proteins, with the first 20 
N-terminal residues of PmaLAAD-01N either 
absent in 1Y56 and in 1C0I, or differently 
oriented if compared to the N-terminal region of 
3ADA and 2GAG (Fig. 6B). We cannot exclude 
that the absence of the anchorage N-terminal helix 
in PmaLAAD-01N, as compared to the full-length 
enzyme, might affect the conformation of the 
following region.  
 
FAD Binding SiteFAD binds to 
PmaLAAD-01N in an extended conformation 
similar to that found in related FAD-binding 
proteins (Fig. 7A) (41). Forty-three residues are 
directly involved in FAD binding (distances 
below 4.5 Å), sixteen of which establish 
electrostatic or polar interactions with the co-
factor. Only five of the latter interactions involve 
side-chain atoms (residues Glu85, Lys86, Gln93, 
Ser94, Thr442), the others being due to main-
chain atoms. The N-terminal ends of the helix 
dipole of A14 and of A1 are pointed toward the 
O2 position of the isoalloxazine ring, and toward 
the pyrophosphate group of FAD, respectively. 
These two dipoles are typical of GR2 family 
members. 
Overall, the isoalloxazine ring is quite 
exposed to solvent, especially at the N5 reactive 
site, located at the interface between the Fdb and 
the Sbd. It establishes hydrogen bonds with the N 
atom of Met441 and the N and OG1 atoms of 
Thr442 (FAD O2 atom), the N atoms of Ser99 and 
Gln100 (FAD O4 atom), and the N atom of Tyr98 
(FAD N5 atom) while displaying van der Waals 
interactions with Gln93, Arg96, Ala97, Tyr98, 
Ser99, Gln100, Leu279, Gln281, Ala410, Val411, 
Val412, Val438, Trp439, Gly440, Met441, and 
Thr442 side chains. The FAD O4 atom is further 
hydrogen bonded to a water molecule located 
inside the active-site cavity (Fig. 7B). 
Furthermore, the model of PmaLAAD-01N 
in complex with N5-sulpho-FAD (generated on 
the basis of the isoalloxazine ring of a N5-sulpho-
flavin mononucleotide, PDB code 1QCW) shows 
that the close vicinity of the PmaLAAD-01N 
helical A2 segment to the FAD N5 reactive site 
would provide steric clash of the bound sulphite 
with the A2-β4 loop (Fig. 7C), thus preventing 
sulphite binding (see above). In addition, the lack 
of such a peculiar feature of the flavo-oxidases is 
also supported by the absence of positively 
charged groups in proximity of the N1-C2=O 
locus of the isoalloxazine ring, whose presence 
would inductively promote the process: in 
PmaLAAD a partial positive charge may be only 
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provided by the dipole associated to the N-
terminus of the nearby helix A14. 
 
Substrate Binding SiteIn order to gain 
structural insight into the substrate-binding mode 
of the enzyme, the structure of PmaLAAD-01N in 
complex with anthranilate (possessing both a 
carboxyl and an amino group, thus mimicking L-
amino acids) was determined at 1.75 Å resolution 
(Rfactor = 15.6%, Rfree = 19.7%). Data collection 
and refinement statistics are reported in Table 1. 
The analysis of the calculated electron density 
map showed the substrate-analogue bond near the 
FAD isoalloxazine moiety (Fig. 8A). 
Binding of anthranilate does not alter the 
PmaLAAD-01N global tertiary structure (r.m.s. 
deviation range 0.43-0.59 Å between complex 
and native structures, depending on the 
superimposed protein chains), nor promote 
quaternary assembly variation. Local differences 
in the backbone conformation are, however, 
evident in the β18-β19 loop, in helix A9 and the 
following loop (Fig. 8A). In particular helix A9, 
which is a 310 helix in the protein, is reorganized 
as a regular -helix in the PmaLAAD-
01N/anthranilate complex. Notably, this region is 
part of the PmaLAAD-01N-specific + 
subdomain and is located at the entrance of the 
substrate-binding pocket. 
Such an entrance is unusually wide (15-20 Å, 
calculated from the C position of residues 
located on opposite sides of the entrance) and 
mainly negatively charged (Glu109, Asp145, 
Asp150, Glu154, Glu341, Asp417, Glu418) (Fig. 
8F). The substrate-binding pocket is deep (≈ 20 
Å) and mostly hydrophobic; the anthranilate 
aromatic ring is stacked to the FAD isoalloxazine 
ring, at a distance of ≈ 4 Å, and located in a pocket 
lined by Leu279, Phe318, Val412, Val438 and 
Trp439. The ligand carboxyl group is H-bonded 
to the NE and NH2 atoms of Arg316 side chain 
(2.8 Å and 3.2 Å, respectively), to the NE2 atom 
of Gln100 side chain (2.9 Å), and to the FAD O4 
atom (3.3 Å), while the 2-amino group of the 
ligand is H-bonded to the carbonyl oxygen of 
Val438 (3.2 Å). Upon ligand binding, Arg316 
changes its conformation dramatically and inserts 
its side chain into the active site and forms an H-
bond, together with Gln100, with anthranilate at 
the re side of the isoalloxazine ring (Fig. 8A,B). 
Additionally, the Phe318 also changes rotamer, 
orienting its side chain parallel to the ligand 
aromatic ring, at a distance of ≈ 5 Å, and the 
structural changes occurring in the 316-318 
region are transmitted to the adjacent 333-343 
region, which is located at the entrance of the 
substrate-binding pocket (Fig. 8A,B).  
The PmaLAAD-01N/anthranilate complex is 
well suited to analyse the binding mode of L-Phe 
(Fig. 8C). The PmaLAAD-01N enzymatic 
activity recorded on the synthetic amino acid L-
Phe ethylester (33% in comparison with L-Phe) 
finds its structural explanation in the presence of 
a pocket lined by Tyr98, Ala314 and Arg316, 
where the ethylester moiety of the substrate fits 
nicely  (Fig. 8D). In contrast, binding of the D-
isomer of Phe would instead result in a steric clash 
between its aromatic side chain and the FAD 
isoalloxazine moiety (Fig. 8E), in keeping with 
the absence of activity assayed for D-amino acids. 
 
 
DISCUSSION 
 
PmaLAAD is a FAD-containing enzyme 
which catalyzes the stereoselective deamination 
of L-amino acids into the corresponding -keto 
acids and ammonia without forming hydrogen 
peroxide, thus differing from known LAAOs. 
PmaLAAD shows a broad substrate specificity 
with a preference for neutral, aromatic L-amino 
acids: the highest activity is apparent for L-Phe, 
L-Leu, L-Met and L-Trp (Table 2). This agrees 
with the size and microenvironment of the 
substrate-binding pocket, which is lined by 
hydrophobic residues (Fig. 8B). 
PmaLAAD is a membrane-bound enzyme. 
Subcellular fractionation and deletion of N-
terminus segments demonstrated that PmaLAAD 
is anchored to the membrane through a putative 
transmembrane -helix (residues 8-28). The 
cellular localization is fundamental for enzyme 
function: accordingly, we demonstrated that 
PmaLAAD is fully active in the presence of 
membranes only. The purified full-length, 
membrane-devoid, PmaLAAD-00N variant is 
practically inactive and the catalytic competence 
is acquired by adding exogenous crude E. coli 
membranes, but is only marginally increased 
using synthetic membranes produced from highly 
pure E. coli lipid extracts (Table 3). These results 
indicate that PmaLAAD requires a specific 
membrane partner for its activity, rather than a 
generic hydrophobic environment of the 
membrane. From spectral evidence (Fig. 4B), and 
because cytochrome c is not considered to be part 
of the main electron transport chain in the Proteus 
genus (37), we propose that the physiological 
electron acceptor from PmaLAAD could be a b-
type cytochrome, a membrane protein that accepts 
electrons from different donors. 
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We demonstrated that the appearance of an 
absorbance spectrum likely corresponding to 
reduced cytochrome b is observed only under 
anaerobic conditions, while under aerobiosis 
electrons are transferred to dioxygen by the 
respiratory chain, as observed using the 
polarographic assay. Indeed, PmaLAAD-00N re-
oxidized very slowly on dioxygen, while in 
DAAOs and LAAOs FADH2 reacted quickly with 
O2 (4,35,47): in PmaLAAD the rate constant for 
FADH2 re-oxidation by O2 is  100-fold slower 
than the turnover number. This limited direct O2 
re-oxidation of FADH2 explains the inability of 
PmaLAAD to produce hydrogen peroxide and 
classifies this enzyme outside the oxidase class of 
flavoenzymes (33), whose members represent the 
closest structural relatives (Fig. 5C and Fig. 6). 
It should be noted that reactivity of 
flavoproteins toward dioxygen is related to the 
microenvironment of their isoalloxazine ring, in 
particular to the presence of positively charged 
residues in proximity of the FAD C4a position. 
For instance, in LAAO from snake venom, 
Lys326 is present on the si face of FAD, and in 
glucose oxidases two His residues are located on 
the re face of the cofactor (48,49). In contrast, in 
PmaLAAD, the corresponding positions in the 
vicinity of the isoalloxazine moiety of FAD are 
occupied by the neutral Gln281 and the 
hydrophobic residues Trp439 and Val438. 
Nevertheless, the isoalloxazine ring is exposed to 
solvent in PmaLAAD, especially at the N5 site 
and its location is compatible with electron 
transfer to a bound acceptor protein. 
The FAD cofactor is bound in an extended 
conformation (Fig. 7A) and establishes a high 
number of interactions with PmaLAAD 
apoprotein, comprising the interaction of helix 
dipole A14 with the O2 of the isoalloxazine ring 
that is expected to stabilize the anionic form of 
FADH2. The isoalloxazine ring is located at the 
interface between the substrate and the FAD-
binding domains and is exposed to solvent, 
especially at the N5 site: its location is compatible 
with electron transfer to the bound acceptor 
protein. 
The overall fold of PmaLAAD resembles 
that of known amine or amino acid 
oxidases/dehydrogenases (Fig. 6) but with 
specific structural features that allow it to fulfil a 
different role, i.e. the deamination of L-amino 
acid with no hydrogen peroxide production to fuel 
the membrane electron-transfer (respiratory) 
chain. Indeed, phylogenetic analysis demonstrates 
that proteins highly homologous to PmaLAAD ( 
28% sequence identity) are present only in the 
Proteobacteria phylum, and in particular in the 
subphyla of alpha-, beta- and gamma-
proteobacteria (Fig. 9). Worthy of note is that all 
related sequences belong to putative flavoprotein 
oxidases or deaminases with unknown function, 
while the sequence identity with known microbial 
DAAOs or LAAOs is quite low (i.e. between 
13.9% and 16.4%). This finding suggests that 
LAADs diverged early from amino acid oxidases 
but conserved a similar active-site organization 
related to the use of the same substrate. In 
common with known amino acid oxidases, 
PmaLAAD shows not only the fold but also the 
ability to generate the anionic semiquinone form 
of FAD during photoreduction, and to produce 
charge-transfer complexes following binding of 
carboxylic acids. 
Different from other flavooxidases, 
PmaLAAD possesses an additional + 
subdomain that is placed in a key (structural and 
functional) region of the protein. As a matter of 
fact, the putative transmembrane α-helix of 
PmaLAAD is bound to the N-terminal end of this 
domain (residues 29-56) while its C-terminal end 
encompasses the region of the active-site entrance 
(helix A9 and following loop) that changes 
conformation upon ligand binding (Fig. 8A). 
Indeed, comparison of the free and anthranilate-
bound structures of PmaLAAD-01N shows that 
part of the active site, in particular Arg316 (which 
binds the carboxyl group of substrate) and Phe318 
(which forms hydrophobic interactions with the 
apolar moiety of the ligand), only acquires the 
correct geometry in the presence of the substrate 
(Fig. 8A). We propose that these conformational 
changes could favour the binding (by electrostatic 
interactions) and correct orientation of the 
substrate at the active site of the enzyme. This 
behaviour is not observed in canonical 
flavoprotein oxidases such as DAAOs or LAAOs 
(4,47,50). 
In summary, we solved the first three-
dimensional structure of a L-amino acid 
deaminase and set up a procedure to prepare a 
stable and soluble preparation of the PmaLAAD 
form (containing membrane fragments) that can 
be employed in cell-free biocatalysis. Overall, 
these results provide the basis for pushing protein 
engineering studies aimed to manipulate LAAD 
substrate specificity in order to fulfil different 
biotechnological requests, such as the resolution 
of racemic mixtures of natural and unnatural 
amino acids or the generation of novel, synthetic 
biochemical pathways (1,51).  
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FIGURE LEGENDS 
 
FIGURE 1. Amino acid sequence of PmaLAAD variants produced in this work. A, scheme of 
produced PmaLAAD variants showing the putative transmembrane α-helix. B, sequence comparison of 
produced PmaLAAD variants; residues are numbered as in PmaLAAD wild-type. Black and grey boxes: 
HisTag and GXGXXG sequences, respectively. PmaLAAD-00N and PmaLAAD-00C possess an 
additional sequence (made of nine and eight residues, respectively) as compared to the wild-type 
enzyme.  
 
FIGURE 2. Purification scheme of recombinant PmaLAAD variants from E. coli cells. A, 
purification scheme of recombinant wild-type PmaLAAD (left), PmaLAAD-00N (centre) and 
PmaLAAD-01N (right). Boxed numbers refer to lanes in the corresponding SDS–PAGE panel B. Gels 
were stained with Coomassie blue; (M) prestained protein ladder. Loaded samples corresponds to 100 
µL of cell culture for PmaLAAD (left) and PmaLAAD-01N (right) and to 50 µL for PmaLAAD-00N 
(centre). S.A. = LAAD specific activity on L-Phe; I.B. = inclusion bodies; F.T. = flow through. 
 
FIGURE 3. Apparent kinetic parameters on L-Phe and pH and temperature dependence of the 
activity of PmaLAAD. A, enzymatic activity of PmaLAAD on the crude extract was determined at air 
saturation by the increase of the product phenylpyruvate, pH 7.5 and 25 °C. Data points were fitted with 
a Michaelis-Menten equation. B, activity of PmaLAAD at 25 °C at the indicated pH values in 
multicomponent buffer (12). Data are expressed as percentage of maximal enzyme activity and were 
fitted based on the equation for two dissociations (12); estimated pKa1 was 5.8 ± 0.1 and pKa2 was 8.3 ± 
0.3. C, activity of PmaLAAD determined at the indicated temperatures. Data are expressed as percentage 
of enzyme activity assayed at 50 °C (the maximum value). In panels B and C, activity was determined 
on 25 mM L-Phe (and at pH 7.5 in panel C) employing 10 L (corresponding to 25 g of enzyme) of 
resuspended membrane containing PmaLAAD fraction. Bars indicate ± SE for three determinations.  
 
FIGURE 4. Spectral properties of PmaLAAD-00N and PmaLAAD-01N variants. A, absorbance 
spectrum of PmaLAAD-00N in the oxidized and reduced form, obtained by anaerobic addition of 25 
mM L-Phe (full line), and of PmaLAAD-01N (dashed line) in the oxidized form. B, absorbance spectrum 
of 17 M PmaLAAD-00N in the oxidized and reduced form (dotted line) by anaerobic addition of 25 
mM L-Phe in the presence of E. coli membranes. Dashed line represents the spectral species obtained 
after the first (faster and wider) reduction phase (see main text). C, D, binding of anthranilate to 15 M 
PmaLAAD-00N and 14.6 M PmaLAAD-01N, respectively. Selected spectra obtained upon addition 
of increasing concentrations of anthranilate are shown. E, binding of kojic acid to 15 M PmaLAAD-
00N; selected spectra obtained upon addition of increasing ligand concentrations (up to 242 mM) are 
shown. F, binding of 2-aminobenzaldehyde (up to 10 mM) to PmaLAAD-01N variant. G, spectra 
recorded at different times during photoreduction of 20 M PmaLAAD-00N; the maximal amount of 
reduced flavin species (dashed line) was detected after 5 min of photoillumination. The photoreduced 
enzyme was anaerobically mixed with benzyl viologen yielding the re-oxidized enzyme after 45 min of 
incubation (dotted line). H, spectra recorded at different times during photoreduction of 17 M 
PmaLAAD-00N in the presence of E. coli membranes (from 280 mg of cells); the maximal amount of 
reduced flavin species (dashed line) was detected after 3.5 min of photoillumination. Bold line: spectrum 
of the original, oxidized enzyme. The arrows in panels indicate the direction of absorbance change at 
increasing ligand concentrations (panels C-F) or at different times (panels G and H). All insets: the 
observed increase in absorbance at selected wavelengths is plotted as a function of the ligand 
concentration: the solid line is a fit of the data to a hyperbolic binding curve. Spectra were recorded in 
50 mM potassium phosphate, pH 7.5 and 15 °C. Kd values reported in the text are the average ± SE of 
3 determinations. 
 
FIGURE 5. Crystal structure of PmaLAAD-01N, topology and structure-based sequence 
alignment. A, schematic view of the domain spatial arrangement in PmaLAAD-01N. The FAD binding 
domain is in green (with the + additional subdomain in blue), the substrate binding domain in orange; 
-helices,  -strands, and coils are represented by helical ribbons, arrows, and ropes, respectively. The 
FAD cofactor is shown in stick representation (yellow color). The N- and C-termini of PmaLAAD-01N 
are labelled. B, secondary structure topology diagram of PmaLAAD-01N: cylinders and arrows indicate 


helices and strands, respectively. C, structure-based sequence alignment of PmaLAAD-01N. 
PmaLAAD-01N is aligned with L-proline dehydrogenase from Pyrococcus horikoshii (PDB code 
1Y56), glycine oxidase from Bacillus subtilis (PDB code 1C0I) and heterotetrameric sarcosine oxidases 
from Corynebacterium sp. U-96 (PDB code 3ADA) and from Stenotrophomonas maltophilia (PDB code 
2GAG). The sequence alignment has been performed using the CLUSTALW program 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) and manually corrected based on their three-dimensional 
structure comparisons. PmaLAAD-01N secondary structure elements are shown on the top of the 
alignment and shaded in gray (yellow for 310 helices) for all aligned proteins. Asterisks and circles 
indicate PmaLAAD-01N residues interacting with the FAD isoalloxazine ring and with anthranilate, 
respectively. 
 
FIGURE 6. Structural comparison with related proteins. A, the structural comparison is produced by 
superimposing the FAD binding domains of PmaLAAD-01N (green, +β subdomain blue) with L-
proline dehydrogenase from Pyrococcus horikoshii (PDB code 1Y56, orange), or glycine oxidase from 
Bacillus subtilis (PDB code 1C0I, magenta), or heterotetrameric sarcosine oxidase from 
Corynebacterium sp. U-96 (PDB code 3ADA, cyan) and from Stenotrophomonas maltophilia (PDB 
code 2GAG, yellow). The FAD cofactor bound to the PmaLAAD-01N is shown in stick representation 
(green color). B, the different orientation of the N-terminus in PmaLAAD-01N relative to the 
heterotetrameric sarcosine oxidase from Corynebacterium sp. U-96 (PDB code 3ADA, cyan) and from 
Stenotrophomonas maltophilia (PDB code 2GAG, yellow) is shown. PmaLAAD-01N Leu52 is labelled 
to indicate the position where the backbone of the three proteins starts to show a good superimposition.  
In both panels the FAD cofactor bound to the PmaLAAD-01N FAD-binding domain is shown in stick 
representation (green color). 
 
FIGURE 7. FAD structure, protein–isoalloxazine ring interactions and active site cavity of 
PmaLAAD-01N. A, simulated annealing (|Fo| - |Fc|) omit electron density map (contoured at 3, grey 
mesh) for the FAD cofactor. The absolute values of the electron density map are reported in the figure 
inset, as calculated by the FFT program implemented in the CCP4i software package (52). The map 
refers to the high resolution data at 1.75 Å, but a similar result can be obtained also from the 2.0 Å 
resolution data (see Table 1). B, the FAD molecule (yellow) and the protein residues (green) located at 
the active site cavity relevant for FAD binding are shown in stick representation and labeled. A water 
molecule is represented as red sphere (0.3 vdW radius). H-bonds are shown by dashed lines. C, model 
of the N5-sulfo-FAD molecule bound to PmaLAAD-01N based on the isoalloxazine ring of a N5-sulfo-
flavin mononucleotide molecule (PDB code 1QCW). 
 
FIGURE 8. Ligand binding to PmaLAAD-01N. A, structural reorganization of the substrate binding 
pocket in PmaLAAD subunit B upon anthranilate binding. The bound anthranilate (ANT) is shown in 
stick representation (cyan) surrounded by its 2Fo-Fc electron density, contoured at 1 (cyan mesh). The 
structure of the PmaLAAD-01N/anthranilate complex (color code as in Figure 5) is superimposed to the 
unbound PmaLAAD-01N (grey) to highligth the backbone differences in the regions 316-318 (the β18-
β19 loop) and 333-343 (helix A9 and the following loop), and the side-chain structural variations of 
Arg316 and Phe318. B, substrate binding pocket in PmaLAAD-01N. The bound anthranilate, the FAD 
molecule and the relevant protein residues are shown in stick representation and labelled. Dashed lines 
indicate H-bonds. For clarity, the A9 region shown in panel A has been omitted. Modeling of the bound 
C, L-Phe, D, L-Phe ethylester, and E, D-Phe, based on the PmaLAAD-01N/anthranilate complex. F, 
entrance of the active site. Molecular surface of PmaLAAD-01N, colored according to its potential (blue 
positive, red negative). The entry of the active site cavity, showing the isoalloxazine ring of FAD 
(yellow) and the bound anthranilate (grey), is clearly visible. 
 
FIGURE 9. Phylogenetic analysis. Proteins homologous to PmaLAAD (> 28% sequence identity) are 
only present in the Proteobacteria phylum, in particular in the subphyla of alphaproteobacteria, 
betaproteobacteria and gammaproteobacteria. Homologous proteins form three main clusters and an 
isolated sequence (B): a group close to PmaLAAD (LAAD) and two large groups (A and C). 
Noteworthy, all identified proteins are putative flavoprotein oxidases or deaminases with unknown 
function. Numbers on the branches represent the percentage of bootstrap samples supporting the branch 
(only values > 50% are shown). PmaLAAD is indicated by an arrow. Sequences were identified by their 
	

UniProtKB Accession Number. 
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FIGURES AND TABLES 
 
TABLE 1 
Data collection and refinement statistics 
Numbers given in parentheses are from the last resolution shell. 
 
Data Collection PmaLAAD-01N PmaLAAD-01N + anthranilate 
X-Ray source ESRF ID23-2 ESRF ID23-1 
Space group P21 P21 
Unit cell dimensions:   
a, b, c (Å) 72.76, 93.71, 74.69 72.81, 93.32, 75.07 
, β, 	 (°) 90, 102.85, 90 90, 103.22, 90 
Resolution (Å) 49.08-2.00 
(2.11-2.00) 
45.90-1.75 
(1.84-1.75) 
Observations 298242 257980 
Unique reflections 65982 96409 
R-merge (%)a 9.4 (51.4) 3.4 (51.3) 
I/(I) 12.0 (2.9) 14.9 (1.9) 
Completeness (%) 99.9 (99.9) 98.1 (97.9) 
Multiplicity 4.5 (4.7) 2.7 (2.7) 
Refinement   
R-factor/R-free (%)b 17.7/20.9 15.6/19.7 
Protein residues in the a.u. 2x447 (28-474) 2x447 (28-474) 
FAD 2 2 
Anthranilic acid - 2 
Water molecules 518 546 
Model quality   
Average B-factor (Å2):   
Protein 26.0 36.8 
FAD 16.2 22.9 
ligand  - 41.8 
water  31.7 43.4 
Rmsd from ideal values:   
bond lengths (Å) 0.006 0.005 
bond angles (°) 1.137 1.098 
Ramachandran plot:   
most favored regions 96.8 96.6 
additional allowed regions 3.2 3.4 
a
 Rmerge = 
h
i | Ihi - <Ih> | / 
h
i Ihi 
b
 Rfactor = 
h ||Fobs| - |Fcalc|| / 
h |Fobs|, with Fobs being the observed and Fcalc the calculated structure factor 
amplitudes 
 
 


TABLE 2 
Relative specific activity of PmaLAAD on different substrates 
The activity was determined by the polarographic assay (oxygen consumption) using a membrane-
containing PmaLAAD preparation and 25 mM substrate concentration with the exception of L-Tyr (1.25 
mM), 3-Phe (12.5 mM), 1-naphthyl-Ala (0.375 mM) and Gly (0.375 mM). The reported value was the 
average of three determinations. *Specific activity was expressed as percentage of the value assessed 
with L-Phe (100%). **The activity value for the corresponding D-amino acid was  4%. ***The activity 
on this compound was confirmed by using for the assay a purified (by re-crystallization) substrate batch 
to avoid contamination by residual free L-Phe. 
 
Amino acid Specific activity (%)*  Amino acid 
Specific activity 
(%)*,** 
Neutral:   Charged:  
Gly 0.06  L-Asp 0.13 
L-Ala 0.59  L-Glu 0.11 
L-Pro 0.96  L-His 9.88 
L-Ile 26.2  L-Lys 3.45 
L-Val 3.47  L-Arg 8.0 
L-Leu 99.2** 
 Unnatural:  
L-Met 86.0**  -Ala 0.21 
Aromatic:   2-Phe 0.24 
L-Phe 100**  3-Phe 0.06 
L-Tyr 13.7  D,L-tert-Leu 9.9 
L-Trp  60.5**  L-Phe amide 2.29 
Polar:   L-Phe-O-ethyl ester*** 33.0 
L-Cys 43.0**  1-Naphtyl-Gly 0.58 
L-Ser 0  1-Naphtyl-Ala 3.75 
L-Thr 0.09  2-Amino octanoic acid 0 
L-Asn 0.74  3-Phenyl-Ser 3.49 
L-Gln 0.55  Glufosinate 0.54 
   D,L-DOPA 56.9 

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TABLE 3 
PmaLAAD-00N activity recovery with purified E. coli lipid extracts  
The activity was determined by the polarographic assay (oxygen consumption) on 25 mM L-Phe as a 
substrate, using ≈ 150 g of purified protein. All mixtures have been sonicated before the assay, until 
the solution appeared completely clear.  
 
Sample Activity (U/mL) 
Increase 
(-fold) 
PmaLAAD-00N (control) 0.25 ± 0.06 1.0 
   
PmaLAAD-00N + membranes from 45 mg cells 7.74 ± 0.37 31.5 
PmaLAAD-00N + 4.5 mg Total Lipid extract 0.98 ± 0.13 4.0 
PmaLAAD-00N + 4.5 mg Polar Lipid extract 0.39 ± 0.11 1.6 
   
PmaLAAD-00N + membranes from 22.5 mg cells 3.45 ± 0.25 14.0 
PmaLAAD-00N + membranes from 22.5 mg cells 
+ 2.25 mg Total Lipid extract 4.96 ± 0.42 20.2 
PmaLAAD-00N + membranes from 22.5 mg cells 
+ 2.25 mg Polar Lipid extract 3.97 ± 0.15 16.1 
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TABLE 4 
Structural comparison of proteins homologous to PmaLAAD-01N 
PDB chain Z 
score 
r.m.s. deviation ali nres Id (%) Protein Ref. 
   all FbD SbD      
1Y56 B 42.3 2.0 
(361) 
1.2 
(179) 
2.0 
(174) 
361 374 23 L-proline 
dehydrogenase 
complex from 
Pyrococcus 
horikoshii 
(44) 
1C0I B 41.2 2.0 
(353) 
1.3 
(176) 
2.2 
(171) 
353 364 21 glycine oxidase 
from Bacillus 
subtilis  
(45) 
3ADA B 40.9 2.2 
(368) 
1.3 
(177) 
1.9 
(175) 
368 397 23 heterotetrameric 
sarcosine oxidase 
from 
Corynebacterium 
sp. U-96. 
(46) 
2GAG B 40.2 2.2 
(368) 
1.3 
(176) 
1.9 
(176) 
368 403 23 heterotetrameric 
sarcosine oxidase 
from 
Stenotrophomonas 
maltophilia 
(19) 
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Figure 9 
 
